Effects of naloxone and fentanyl in acutely decerebrated dogs

Hyperalgesic and analgesic actions of morphine, U50-488, naltrexone, and (-)-lobeline in the rat brainstem

Morphine, U50-488, and (-)-lobeline produced dose-related shortening of a low-intensity thermally evoked tail avoidance response (LITETAR) (e.g., hyperalgesia) when microinjected into the dorsal posterior mesencephalic tegmentum (DPMT) of conscious rats. The hyperalgesic potency of (-)-lobeline was greater than either morphine or U50-488. With higher doses, morphine's hyperalgesic actions diminished and prolongation of the LITETAR (e.g., analgesia) was observed. Naltrexone produced analgesia in the DPMT that diminished with increasing dose. The hyperalgesic actions of morphine, U50-488, and (-)-lobeline further suggest the presence of kappaergic opioid and nicotinic mechanisms in the DPMT of rats. The hyperalgesic actions of U50-488, a highly specific opioid kappa-receptor agonist, strongly suggest the presence of a kappa-opioidergic hyperalgesic mechanism in the DPMT.

Diurnal variation in plasma ir-beta-endorphin levels and experimental pain thresholds in the horse

Diurnal variation in nociceptive sensitivity and plasma immunoreactive beta-endorphin (ir-BEND) concentrations was examined in eight healthy Thoroughbred horses. Pain thresholds, ir-BEND concentrations, rectal temperature, heart rate, respiratory rate and pupil diameter were measured over a 24 hour period. Nociceptive sensitivity was determined using two objective measures of pain: the skin-twitch reflex latency and the hoof withdrawal reflex latency. Significant variation in both nociceptive thresholds and ir-BEND concentrations were noted over the 24 hour period, with elevated pain thresholds observed at 0900 hours and smaller secondary peaks at 1500 hours. Immunoreactive beta-endorphin concentrations were also elevated at 0900 hours. Cardiac rate was high and pupil diameter was largest at 0900 hours. These physiologic changes, along with increased pain threshold, mimic the observed effects of morphine and other mu-agonists in the horse. The results of this study suggest that endogenous opioid peptides may modulate pain threshold as well as other physiologic parameters in the horse.

Analgesic actions of dynorphin A(1–13) antiserum in the rat brain stem

This study was performed to evaluate the effects of dynorphin A(1-3) antiserum when microinjected into an active hyperalgesic region within the rat brain stem. When administered within the dorsal posterior mesencephalic tegmentum (DPMT) of intact conscious rats, dynorphin A(1-13) antiserum produced rapid onset and persistent prolongation of a low intensity thermally evoked tail avoidance response (LITETAR). These analgesic actions of the dynorphin A(1-13) antiserum appeared to be dose dependent. These studies support previous hypotheses about the existence of tonically active brain stem opioid hyperalgesic process. Further, the results provide indirect evidence for a potential role of brain stem dynorphin(s) in facilitating pain.

Thermally evoked tail avoidance reflex: input-output relationships and their modulation

Latency to onset and magnitude (angular displacement) of thermally evoked tail avoidance reflexes (TETAR) to graded thermal stimuli were measured in pentobarbital-treated and untreated rats. The latency to onset was inversely and the magnitude was directly proportional to the thermal stimulus intensity. Pentobarbital prolonged the latency to onset of the TETAR to low by not high stimulus intensities. Activation of (-)-nicotine sensitive brainstem hyperalgesic processes shortened the latency and increased the magnitude of the TETAR. The hyperalgesic actions of (-)-nicotine were most demonstrable at lower thermal stimulus intensities. These studies suggest that the TETAR is graded in intensity as the stimulus intensity is increased and that the response evoked by different intensities of stimulus probably involve common neurophysiologic mechanisms.

Cardiovascular and respiratory effects of an opioid kappa agonist ethylketazocine and sigma agonist N-allylnormetazocine in acutely decerebrated dogs

Effects of opioid kappa agonist ethylketazocine (EKC), sigma agonist (+-)-N-allylnormetazocine (NANM), and naloxone alone and in combination on mean blood pressure (MBP), heart rate (HR), respiratory rate (RR) and minute volume (MV) were studied in acutely decerebrated dogs. EKC (0.5 mg/kg) decreased HR, MBP, RR and MV. Post-EKC NLX increased RR and MV and reversed the bradycardia and hypotension produced by EKC. NANM (1 mg/kg) produced respiratory depression and tachycardia without changing MBP. Post-NANM NLX antagonized tachycardia, increased MBP, however did not significantly change RR and MV. When decerebrate dogs were spinalized at the C-1 level, EKC decreased MBP and HR. These effects were antagonized by NLX. NANM did not change HR but raised MBP in spinalized decerebrate dogs. Since EKC- and NANM-induced cardiovascular and respiratory depression were not observed in conscious intact or chronic spinal dog, it is suggested that: 1) kappaergic system rostral to mesencephalon may play a role in counteracting these depressant effects of EKC; 2) sigma receptor-mediated tachypnea and tachycardia are dissociable; the tachypneic effect may be mediated through higher center while the medulla oblongata is involved in producing tachycardia. These results also suggest that (+-)-NANM probably has several mechanisms of action at several brain sites in producing its effects on respiration and cardiovascular function.

Potentiation of disruptive effects of dextromethorphan by naloxone on fixed-interval performance in rats

A centrally acting antitussive agent dextromethorphan (DM) was tested to determine its possible interaction with naloxone in rats responding under a fixed-interval schedule of positive reinforcement. A sugar sweetened milk reward was used as a positive reinforcer. Under the same experimental conditions the effects of morphine alone and in combination with naloxone were also determined. Low dose DM (10 mg/kg) produced a slight increase, while higher doses (20-40 mg/kg) produced dose-dependent decreases in response rate. Morphine (0.3, 1.0 and 3.0 mg/kg) produced dose-dependent decreases in response rate. When doses of naloxone (0.1-1.0 mg/kg) were administered after the injection of DM the rate-decreasing effects of DM were potentiated even after the rate-increasing dose of naloxone (0.1 mg/kg) was used. When a dose of naloxone (0.1 mg/kg) was administered after the injection of morphine the rate-decreasing effects of morphine were markedly antagonized, i.e., the morphine dose-response curve was shifted to the right. The observed potentiation of DM disruption by naloxone on fixed-interval performance in rats is consistent with findings showing that naloxone potentiates the disruptive behavioral effects of a number of drugs that are psychotomimetic in man.

Differential effects of clonidine on pain, arterial blood pressure, and heart rate in the cat: lack of interactions with naloxone

In cats anesthetized with alpha-chloralose and urethane, intravertebral administration of clonidine (4 and 10 micrograms/kg) dose-dependently suppressed the jaw-opening reflex, arterial blood pressure, and heart rate. For a given dose, there was a differential degree of inhibition in the order of analgesia much greater than hypotension greater than bradycardia. Naloxone injections (0.4 and 1.0 mg/kg, i.vert.) essentially failed to antagonize these effects, suggesting the lack of involvement of the opiate receptors or endogenous opioids in these processes. Furthermore, pain suppression by clonidine appeared to be independent of the vasodepression and cardioinhibition it promoted. It is possible that neural mechanisms responsible for clonidine-induced antinociception, hypotension, and bradycardia are likely to have differential sensitivities to the imidazoline compound, regardless of whether they exist in separate central sites or in subpopulations of neurons within common neural substrates.

Possible medullary kappa hyperalgesic mechanism. I. A new potential role for endogenous opioid peptides in pain perception

The kappa-agonist, ethylketazocine, produces hyperalgesia in the acutely decerebrated dog as indicated by a shortening of the skin twitch reflex latency whereas fentanyl is inactive. Naloxone produces analgesia and antagonizes the hyperalgesic effect of ethylketazocine. Spinal cord transection decreases the latency of the skin twitch reflex and allowed the analgesic effect of fentanyl and ethylketazocine on this nociceptive reflex to become manifest. These observations indicate that there is a non-opioid analgesic and kappa hyperalgesic mechanism present in the pontine-medullary region of the dog brainstem. It suggests that the hyperalgesic mechanism is mediated by an endogenous kappa-opioid peptide and that the analgesic effect of naloxone is in part related to antagonism of the activity of this hyperalgesia producing opioid peptide.